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Aim: The evaluation of mutagenic properties of imidapril hydrochloride (IMD) and its degra-
dation impurity, diketopiperazine derivative (DKP), nitrosation mixtures was conducted in
order to analyze the carcinogenic risk of IMD long-term treatment in patients. In this study
an  in vitro Ames test with Salmonella enterica serovar Typhimurium TA 98 and TA 100 strains
was  used.
Background: IMD and DKP contain nitrogen atoms, which makes them theoretically vulner-
able to in vivo nitrosation with the production of N-nitroso compounds (NOC). NOC, in turn,
are  known animal mutagens indicating that their endogenous production from nitrosable
drugs constitutes a carcinogenic hazard.
Materials and methods: Pure IMD sample was exposed to forced degradation conditions of
increased temperature and dry air in order to achieve a DKP sample. Both samples were
then  treated with a nitrosating agent and the obtained nitrosation mixtures were subjectedto  mutagenicity analysis by the Ames test with S. typhimurium TA 98 and TA 100 strains in
the presence and absence of metabolic activation system (S9 mix) using a commercial Ames
MPF  98/100 microplate format mutagenicity assay kit.
Results: None of the six concentrations of the investigated nitrosation mixtures exhibited
any  mutagenic potential in both S. typhimurium strains. The addition of S9 mix  did not alterthe  non-mutagenic properties of the studied compounds.
∗ Corresponding author at: Greater Poland Cancer Center, 15th Garbary Street, 61-866 Poznan, Poland. Tel.: +48 618850645;
fax:  +48 618850647.
E-mail address: katarzyna.regulska@wco.pl (K. Regulska).
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Conclusions: The nitrite treatment of both studied compounds has no impact on their muta-
genic properties under the conditions of the present studies. Hence, IMD and DKP nitrosation
mixtures are classiﬁed as non-mutagens in this test.
© 2014 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
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r.  Background
-nitroso compounds (NOC) are the group of chemicals that
ontain the N O functional attached to a nitrogen atom
f an organic moiety.1 They are commonly present in food
reated with sodium nitrite, cosmetics, pharmaceutical prod-
cts, tobacco smoke, drinking water and air.2 In multiple
reclinical experiments, they have been shown to induce
arcinogenic and tumor-promoting effects in as much as
9 species of laboratory animals, including higher primates.
urthermore, there is a supporting evidence conﬁrming the
articipation of various NOC in the development of several
uman neoplasms including: gastric, esophageal, nasopha-
yngeal, pancreatic, colon and brain cancer.3–6 The occurrence
f NOC-induced malignancies results generally from a large-
cale human exposure to these compounds which can be
oth, exogenous (as listed above) and endogenous after their
n vivo formation from N-nitrosable precursors and nitrosat-
ng agents in the strongly acidic environment of gastric
uice.4 In fact, NOC precursors can be easily recognized by
he presence of several functional groups, such as: dialkyl-,
lkylaryl-, diaryl-, cyclic secondary amine, tertiary amine,7,8
-alkylurea, N-alkylcarbamate, N-alkylamide, cyanamide,
uanidine, amidine, hydroxylamine, hydrazine, hydrazone,
ydrazide, piperazine4 and probably diketopiperazine.9,10
hese chemical structures, in turn, are commonly present in
 large fraction of the available drug molecules making them a
ossible source of NOC in vivo. Indeed, a wide array of drugs is
nown to produce NOC after treatment with nitrosating agent
nd many  of these nitrosation products have been proven
o exert mutagenic actions.4 Thus, the mutagenicity assess-
ent for N-nitrosable drugs seems to be a reasonable means
f cancer prevention aimed at the reduction of the risk asso-
iated with patient exposure to mutagenic and carcinogenic
rugs.
The induction of genome mutations (especially point
utations in human oncogenes or tumor suppressor genes)
s the most common mechanism by which drugs could
ontribute to cancer development.11 A simple method that
etermines the patterns of missense mutations, commonly
sed for mutagen screening and recommended by regula-
ory agencies, is the in vitro bacterial reverse mutation assay
Ames test). This test is designed to detect a point mutation-
nducing activity of investigated compounds, evidenced by
he alternation of growth requirements of tester organisms.12
nfortunately, the analysis of the possible in vivo NOC pro-
uction from nitrosable drugs and the assessment of their
utagenicity still remains outside the regulatory recom-
endations for standard carcinogenicity tests prior to drug
egistration.4Another important aspect that needs consideration with
respect to carcinogenic risk associated with the use of
N-nitrosable drugs is their constant chemical degrada-
tion that leads to the formation of degradation impurities
present in ﬁnal dosage forms. Drug decay is, in fact, an
unavoidable process resulting from a multi-component and
multi-phase character of each formulation, causing the grad-
ual loss of drug’s potency and the accumulation of its
degradation products.13 This, in turn, indicates that the
administration of rapidly-degrading pharmaceuticals is asso-
ciated with patient exposure to their degradants which
similarly to active ingredients could present the potential
for N-nitrosation. For this reason, the appropriate stability
tests, identiﬁcation of drug degradation impurities, evalu-
ation of their N-nitrosating tendency and assessment of
their ability to induce genome mutations seem essen-
tial for safety assurance especially with respect to cancer
initiation.
The subject of our studies, imidapril hydrochloride (IMD),
is an angiotensin-converting enzyme inhibitor (ACE-I) indi-
cated for the long-term treatment of essential hypertension.14
The presence of nitrogen atoms in IMD molecule makes
it theoretically N-nitrosable (Fig. 1). What is more,  the
previously-performed stability assessment of this drug proved
that IMD  undergoes the process of degradation, acceler-
ated by heat and moisture, following different pathways
dependent on the environmental conditions.15 Under high
moisture conditions, IMD decay results in the production of
two degradation impurities, i.e.:  a diacidic derivative (imidapri-
lat), which is an active metabolite, and a diketopiperazine
derivative (DKP)16; however, under dry air conditions, IMD
forms only one degradation impurity identiﬁed as DKP.17
The structural analysis of the formed degradation impuri-
ties indicates that these compounds, like IMD,  demonstrate
the vulnerability to N-nitrosation, rising some justiﬁed safety
concerns. It should, however, be emphasized that the non-
mutagenic character of pure IMD and its active metabolite
has been conﬁrmed in the course of its legal registration
process.18 Furthermore, our previous mutagenicity studies
of pure DKP with Salmonella typhimurium TA 98 and TA
100 strains, both with and without metabolic activation
system, showed a negative result, conﬁrming no impact
of pure degradation impurity on cancer initiation by  the
mechanism of mutagenesis.17 However, some available litera-
ture data demonstrate that other structurally-related ACE-Is,
such as enalapril, do exhibit a mutagenic potential in S.
typhimurium TA 1535 strain after N-nitrosation (1.12 mg/mL).19
Moreover, there is evidence that the chemicals containing
diketopiperazine motif could be carcinogenic to humans
after exposure to nitrite in the environment of gastric
juice.9,10
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ationFig. 1 – Pathways of IMD  degrad
2.  Aim
The aim of our study was to assess the mutagenic hazard of
IMD  and DKP nitrosation mixtures in order to investigate their
impact on cancer initiation and conﬁrm safety of IMD-based
therapy. We  did not aim at the mutagenicity evaluation of pure
imidaprilat because of its close structural similarity to IMD
(Fig. 1) suggesting the analogy of their chemical properties.
Our adopted analytical approach involved the exposure
of pure IMD  sample to stress conditions of increased tem-
perature and dry air according to the previously-established
procedure in order to achieve a DKP sample.17 For the iden-
tiﬁcation of the obtained degradation impurity a RP-HPLC
method was applied. Pure IMD  and DKP were subsequently
subjected to N-nitrosation according to NAP test criteria4,20and the obtained nitrosation mixtures were ﬁnally analyzed
for their cytotoxicity and mutagenicity using a commercial
Ames MPF  98/100 microplate format mutagenicity assay kit
with S. typhimurium TA 98 and TA 100 strains exposed to under different RH conditions.
six concentrations of tested compounds in the presence and
absence of a metabolic activation system.12
3.  Materials  and  methods
3.1.  Chemicals
3.1.1.  IMD  degradation  procedure
Imidapril hydrochloride was supplied by Jeleniogorskie Zak-
lady Farmaceutyczne “JELFA” (Jelenia Gora, Poland). Analytical
grade potassium phosphate monobasic and ortho-phosphoric
acid were obtained from POCh S.A. (Gliwice, Poland) and HPLC
grade methanol and acetonitrile were purchased from Merck
KGaA (Darmstadt, Germany). Bidistilled water was used.3.1.2.  Nitrosation  procedure
Analytical grade hydrochloric acid 1.0 mol/L, sodium nitrite
(NaNO2) and ammonium sulfamate (NH4SO3NH2) were
obtained from Sigma–Aldrich. Ultrapure water was used.
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.1.3.  Mutagenicity  assay
 commercial Ames MPF  98/100 microplate format mutageni-
ity assay kit (Xenometrix, Switzerland) with S. typhimurium
trains TA 98 (hisD3052, rfa uvrB, pKM101) and TA 100
hisG46, rfa uvrB, pKM101) was used. It contained the fol-
owing chemicals: 2-nitroﬂuorene, 4-nitroquinolone-N-oxide,
-aminoanthracene as positive controls, phenobarbital/-
aphtoﬂavone-induced rat liver fraction S9 as the activation
ystem, sterile ampicillin (50 mg/mL), growth medium, expo-
ure medium (histidine-rich) and indicator medium (lacking
istidine). The S9 mix  was prepared by the use of a commer-
ial kit from Xenometrix containing phosphate buffer pH 7.4,
gCl2, KCl, G-6-P and NADP. The tested samples were diluted
n sterile DMSO (Sigma–Aldrich).
.2.  Apparatus
.2.1.  RP-HPLC  method
 Shimadzu liquid chromatograph comprising a Rheodyne
125, 100 L ﬁxed loop injector, UV-VIS SPO-6AV detec-
or, LC-6A pump and C-RGA chromatopac integrator was
sed. The chromatographic separation was performed under
he following conditions: LiChrospher 100 RP-18 (size 5 m)
50 mm × 4 mm I.D. column as a stationary phase and
cetonitrile–methanol–aqueous phosphate buffer, pH 2.0;
.035 mol/L (60:10:30, v/v/v) as a mobile phase. Aqueous phos-
hate buffer was prepared by dissolving 68.1 mg  of potassium
ihydrogen phosphate (KH2PO4) in 450 mL  of bidistilled water.
he obtained solution was further adjusted to desired pH
.0 with 1.0 mL  of phosphoric (V) acid (85%) and then it was
ompleted to the volume of 500.0 mL  with bidistilled water.
he mobile phase had been ﬁltered (ﬁlter 0.22 m),  degassed
y ultrasound and pumped isocratically at a ﬂow rate of
.2 mL/min at ambient temperature. The detector wavelength
as 218 nm and the injection volume was 20 L.21
.2.2.  Bacterial  reverse  mutation  assay
 Dry Incubator KBC-125W (WAMED) set at 37 ◦C and
icroplate shaker DTS-4 were used for the incubation of the
ester strains. The optical density (OD600) of the overnight
ulture was measured by UV-VIS spectrophotometer, Lambda-
 UV WinLab Version 2.70.01, Perkin Elmer. The analytical
perations were performed under safety cabinet so that no
ontamination of the cultures could occur.
.3.  Procedures
.3.1.  Obtainment  of  DKP  sample
ure IMD  was analytically weighted (200.0 mg  for a mutage-
icity study and 10.0 mg  as a reference) into glass vial and
laced in a sand bath that ensured the appropriate conditions
f relative air humidity (RH 0%). The so prepared samples were
eated to 100 ◦C for 15 days so as to induce the process of
ccelerated drug degradation. Afterwards, the degraded IMD
ample (10.0 mg)  was cooled to room temperature, dissolved
n bidistilled water, quantitatively transferred into volumetric
ask, made up to a total volume of 25.0 mL  with methanol,
ltered and chromatographed by RP-HPLC method in order totherapy 1 9 ( 2 0 1 4 ) 412–419 415
conﬁrm its qualitative and quantitative composition by com-
paring the obtained chromatogram with the reference.17
3.3.2.  Nitrosation  procedure
The nitrosation of IMD and DKP was performed according
to the ‘nitrosation assay procedure’ (NAP test) recommended
by a WHO  Expert group.4,20 The samples of the investigated
chemicals (125.0 mg)  were dissolved in 1.0 mL  of sterile DMSO,
adjusted to pH 3 with 1 M hydrochloric acid and treated with
sodium nitrite (NaNO2) in the molar ratio of 1:4. Then pH was
again adjusted to 3. The so obtained nitrosation mixtures were
incubated for 1 h at 37 ◦C in the dark on a shaker. The solvent
(sterile DMSO) with nitrite treatment was incubated under
similar conditions as a negative control for the mutagenicity
assay. The reaction was subsequently stopped by the addition
of ammonium sulfamate (molar ratio NaNO2 vs.  NH4SO3NO2
was 4:4). The obtained reaction mixtures were subjected to a
cytotoxicity and mutagenicity assay. The concentrations of the
tested nitrosation products were expressed as a concentration
of the parent compounds prior nitrosation.
3.3.3.  Preparation  of  test  bacterial  strains
The S. typhimurium strains TA 98 and TA 100 were cultured
overnight (16 h) in a histidine-rich medium at 37 ◦C on a shaker
in the presence of ampicillin and only cultures with optical
density above 2.0, measured at  = 600 nm (OD600), were used.
3.3.4.  Cytotoxicity  assay
Pre-screen determination of dose range was performed prior
to mutagenicity analysis by the evaluation of cytotoxicity
of the tested compounds. With this aim, TA 98 strain was
used. The nitrosation mixtures were sequentially diluted on
a 96-well plate so that the following primary concentra-
tions were obtained: 113.2 mg/mL, 35.95 mg/mL, 11.44 mg/mL,
3.64 mg/mL, 1.16 mg/mL, 0.37 mg/mL, 0.118 mg/mL. Aliquots
of 10.0 L of each primary concentration were trans-
ferred to 24-well plate and diluted with 240.0 L of
the mixture prepared beforehand by mixing 2.7 mL  of
an exposure medium with 0.3 mL of the overnight cul-
ture. The following exposure concentrations were thus
obtained: 4.5 mg/mL, 1.44 mg/mL, 0.46 mg/mL, 0.15 mg/mL,
0.046 mg/mL, 0.015 mg/mL, 0.0047 mg/mL. The analysis was
performed in parallel with a negative control (30.0 L) obtained
as described in Section 3.3.2. The so prepared solutions were
incubated on a shaker at 37 ◦C for 90 min. The lowest con-
centration for which the lysis of bacteria was observed was
accepted as the highest concentration for the mutagenicity
assay.
3.3.5.  Ames  test
The mutagenicity assay was performed according to manu-
facturer instructions. The selected S. typhimurium strains were
exposed to six concentrations of the tested nitrosation mix-
tures, both with and without rat liver S9 fraction. The stock
solutions of positive controls in DMSO necessary for analy-
sis were prepared as demonstrated in Table 1. The nitrosation
mixtures were sequentially diluted with sterile DMSO, trans-
ferred to 24-microwell plates and mixed with 240 L of the
previously prepared mixture containing an exposure medium
(histidine-rich), overnight culture and 4.5% microsomal S9
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Table 1 – Positive controls applied for the mutagenicity assay.
S. typhimurium strain Positive control Stock solution Final concentration
Without metabolic activation
TA 98 2-Nitroﬂuorene 50.0 g/mL 2.0 g/mL
TA 100 4-Nitroquinolone-N-oxide 2.5 g/mL 0.1 g/mL
With metabolic activation induced with phenobarbital/ˇ-naphtoﬂavone
TA 98 2-Aminoanthracene 12.5 g/mL 0.5 g/mL
31.25 g/mL 1.25 g/mL
Fig. 2 – RP-HPLC chromatogram of degraded IMD sampleTA 100 2-Aminoanthracene
fraction (if necessary) so that the following ﬁnal test concen-
trations in triplicate were produced: 0.14 mg/mL, 0.28 mg/mL,
0.56 mg/mL, 1.125 mg/mL, 2.25 mg/mL, 4.5 mg/mL. They were
incubated for 90 min  at 37 ◦C in parallel with positive and neg-
ative controls. Afterwards, the exposed cultures were diluted
in a specially formulated medium containing a pH indicator
and lacking histidine, and the contents of each 24-well cul-
ture were distributed into 48 wells of a 384-well plate (50 L
per well) to be incubated for 48 h. Mutagenicity was measured
by a color change from purple to yellow caused by pH drop
due to bacterial metabolism. The scoring of colonies that had
undergone the reversion to histidine prototrophy was per-
formed manually. A sample was considered positive when
there was at least a twofold increase over the baseline (FIB > 2)
and a positive dose–response tendency occurred. The base-
line was deﬁned as the mean number of positive wells in
the negative controls plus one standard deviation (SD). The
dose–response relationship was described by the increase in
at least three consecutive doses maintaining statistical signif-
icance expressed as p-value below 0.05. The statistical criteria
of the t-test were evaluated as a supplementary means of
results interpretation.
FIB = mean number of positive wells/zero-dose baseline
Baseline = mean zero-dose control + 1 SD
4.  Results
The 15-dayed stressing of IMD  sample caused the complete
degradation of the drug (IMD content in the sample ∼0%)
and the formation of DKP (content in the sample ∼100%) as
evidenced by the recorded RP-HPLC chromatogram (Fig. 2)
which was compared with the reference.17
The pre-screen determination of dose range evidenced that
none of the tested concentrations of the analyzed nitrosa-
tion mixtures exhibited any cytotoxicity signs of increased
bacterial lysis. A bacteria growth was observed in each well
indicated by the liquid turbidity comparable to zero-dose.
Thus, according to Organization for Economic Co-operation and
Development Recommendations – OECD guideline 471 adopted at
21 July 1997, the concentration of 4.5 mg/mL  was selected as
the highest concentration for mutagenicity assay.The revertant frequencies obtained in the mutageni-
city assay of the analyzed nitrosation mixtures for both S.
typhimurium strains with and without metabolic activation are
demonstrated in Figs. 3 and 4.after 15-dayed stressing under T = 100 ◦C and RH = 0%.  2 –
IMD  (tR = 5 min); 1 – DKP (tR = 3 min).
5.  Discussion
The performed studies were aimed at the evaluation of car-
cinogenic hazard associated with the administration of the
theoretically-nitrosable drug, IMD and its impurity, DKP which
is formed in the course of IMD degradation and, thus, is
present in the ﬁnal dosage form. As indicated by the path-
ways of IMD decay (Fig. 1), its exposure to stress conditions
of increased temperature and dry air leads to the formation
of pure DKP.17 Hence, by applying the previously-established
and validated procedure of accelerated IMD  degradation for
15 days we  achieved the desired compound and its pres-
ence in the studied sample was conﬁrmed by comparing the
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Fig. 3 – The results of bacterial reverse mutation test with TA 98 and TA 100 strain in the presence and absence of metabolic
activation for IMD  nitrosation mixture. Dashed line corresponds to FIB = 2.
Fig. 4 – The results of bacterial reverse mutation test with TA 98 and TA 100 strain in the presence and absence of metabolic
activation for DKP nitrosation mixture. Dashed line corresponds to FIB = 2.
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obtained RP-HPLC chromatogram with the reference one.17
Since both chromatograms represented a high level of anal-
ogy – the retention times of the peaks for IMD  (tR = 5 min) and
DKP (tR = 3 min) were comparable, and the DKP content was
∼100% (Fig. 2), we accepted the sample for further studies.
Both IMD  and DKP exhibit the theoretical capacity of form-
ing NOC in vivo, thus, in our research they were subjected to
nitrosation under the standard conditions established by NAP
test guidelines. The applied nitrosation procedure provided
an excess of nitrite to promote the reaction and ensured the
optimal temperature and pH for the highest reaction efﬁciency
so that the sensitivity of the analysis could be maximized. It
should, however, be emphasized that the so obtained prod-
uct yields exceed by far the clinically reachable NOC levels
in vivo and thus the employed scientiﬁc approach was used
only as a reference test to screen and discriminate between
compounds that represent a potential risk and drugs with low
N-nitrosation potential.
Cytotoxicity assay for both nitrosation mixtures was fur-
ther performed as a pre-screen determination of a dose range
in order to ensure the highest sensitivity of the Ames test.
This procedure was in agreement with OECD guideline 471.
In fact, all the tested concentrations were found to be non-
cytotoxic indicating that the highest one can be applied to the
mutagenicity assay.
The mutagenicity of both nitrosation mixtures was ﬁnally
investigated. For this purpose the bacterial reverse mutations
assay was selected. This test is recommended by ICH guide-
line CMPH/ICH/174/95 which approves it as a standard method
for pharmaceutical genotoxicity testing. It utilizes the spe-
cially engineered S. typhimurium strains that detect either
frameshift (TA 98 with hisD3052) or base-pair substitution
(TA 100 with hisG46)  mutations so that mutagens acting via
different mechanisms may be identiﬁed. Thus, by the appli-
cation of the Ames test we  evaluated the capability of the
investigated nitrosation mixtures (expressed as FIB value) to
reverse the histidine-dependent, auxotrophic mutants of S.
typhimurium to the protrophic forms that can grow on a growth
factor-deﬁcient medium. The critical FIB value for the clas-
siﬁcation of positive results was accepted as 2. We found
that none of the tested concentrations for both S. typhimurium
strains exhibited a twofold increase of revertant number over
the baseline (FIB below 2). What is more,  the addition of
S9 mix  did not affect the mutagenicity of the tested com-
pounds in both strains. Also, no dose–response tendency was
observed for IMD  nitrosation mixture in both strains, for DKP
nitrosation mixture in TA 98 strain and for DKP nitrosation
mixture in TA 100 with S9 mix, indicated by a low value of
the correlation coefﬁcient (r < 0.818). However, DKP nitrosation
mixture with TA 100 strain without metabolic activation (S9-)
gave a dose-related increase over the tested range (correla-
tion between concentration and revertants number r = 0.960),
while the result for the highest concentration was close (but
below) to the adopted criteria of reproducible increase in rever-
tants number. Since three consecutive concentrations with
p-value below 0.05 were assumed as minimum to determine
the dose–response as not random, the obtained result was
interpreted as negative. Therefore, since none of the tested
compounds met  the criteria for positive result classiﬁcation,
it was concluded that the exposure to nitrosating agent doesiotherapy 1 9 ( 2 0 1 4 ) 412–419
not inﬂuence the non-mutagenic properties of tested chem-
icals under the conditions of this study, indicating that the
tested chemicals have no impact on cancer initiation by this
mechanism. Basing on the obtained results, also some real-
life implications can be made. According to literature data, the
maximum blood concentration of IMD  after 28-dayed admin-
istration equals 34.7 ng/mL22 which is as much as 106 less
than the concentration range tested. This indicates that the
clinically obtainable level of its nitrosation and degradation
product is even lower, advocating our no-effect argument. It
should, however, be emphasized that CPMP/ICH/141/95 and
CPMP/ICH/174/95 guidelines issued by ICH recommend the
performance of additional studies, such as: in vitro assay with
mammalian cells and in vivo experiments with laboratory ani-
mals as a corroborative evidence prior to ﬁnal classiﬁcation of
a drug as a non-mutagen.
6.  Conclusions
Exposure to nitrosating agent has no impact on IMD  and DKP
mutagenic properties under the conditions of the present test.
Just like pure compounds, IMD and DKP after nitrite treatment
give a negative result in the Ames test with S. typhimurium TA
98 and TA 100 strains, both with and without metabolic acti-
vation system (S9 mix). These results indicate that the in vivo
nitrosation of IMD and its degradation impurity probably has
no impact on cancer initiation by the mechanism of mutagen-
esis studied in our research. However, an appropriate clinical
trial is necessary in order to conclusively conﬁrm our results.
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